Dr. Levi Garraway to Deliver NCI CURE Distinguished Scholars Seminar
, by CRCHD Staff
CRCHD is delighted to welcome Dr. Levi Garraway as the featured speaker for the next lecture in the NCI’s Continuing Umbrella of Research Experiences (CURE) Distinguished Scholars Seminar.
Dr. Garraway is Senior Vice President of Global Oncology and Medical Affairs at Eli Lilly and Company, and Associate Professor of Medicine in the Medical Oncology Service at the Dana-Farber Cancer Institute and Broad Institute. He is Director of the Joint Center for Cancer Precision Medicine and Co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center. Dr. Garraway is internationally recognized for his work on genomic alterations in cancer for the purpose of identifying therapeutic interventions and has authored nearly 200 peer-reviewed scientific articles.
In his lecture, Molecular and Genomic Characterization of Human Solid Tumors, Dr. Garraway will discuss combined genomic and functional approaches to the characterization of human solid tumors and how these integrative approaches offer promise to aid investigators and patients in identifying rational cancer therapeutics.
This seminar will take place on Tuesday, July 24, 2018, from 2:00–3:30 PM ET at the NCI Shady Grove campus in TE406. For those unable to attend in person, a webinar option is available. Webinar attendees should click here to register in advance.
The CURE Distinguished Scholars Seminar Series was launched in 2017 as part of the 21 Years of the CURE Program celebration. This semiannual scientific seminar series aims to recognize CURE scholars who have made seminal contributions to the fields of cancer and cancer health disparities research and are role models and mentors for other scientists from backgrounds underrepresented in cancer research.
This October, CRCHD will host former CURE scholar, Dr. Chanita Hughes-Halbert. Dr. Hughes-Halbert is a Professor and Distinguished AT&T Endowed Chair in Cancer Equity at the Medical University of South Carolina and a nationally recognized expert in cancer prevention and control among diverse populations. She recently was elected into the National Academy of Medicine.
The CURE program supports underrepresented individuals across the academic continuum—beginning in middle school and continuing to cancer research independence—through a pipeline of research funding opportunities.